CEEP + rituximab

CEEP + rituximab is a high-dose chemoimmunotherapy regimen consisting of the chemotherapy combination CEEP (cyclophosphamide, epirubicin, etoposide, and prednisone) administered alongside the anti-CD20 monoclonal antibody rituximab. This regimen is primarily utilized as a high-dose conditioning therapy followed by autologous stem cell transplantation (ASCT) for patients with diffuse large B-cell lymphoma (DLBCL). Rituximab targets the CD20 antigen on B-lymphocytes, inducing cell death through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The chemotherapy components provide synergistic cytotoxic effects: cyclophosphamide acts as a DNA alkylating agent; epirubicin and etoposide inhibit DNA topoisomerase II, leading to DNA strand breaks and apoptosis; and prednisone serves as a lympholytic corticosteroid. This specific protocol was evaluated in clinical trials led by Nantes University Hospital and the GOELAMS group to compare high-dose therapy against standard CHOP-14 plus rituximab in frontline settings for high-risk DLBCL patients.

Other names

CEEP-RituximabRituximab-CEEPCyclophosphamide + Epirubicin + Etoposide + Prednisone + Rituximab